Skip to content

Shop
Scholar
Lab Results
Learn
Vote
Forum
About

Search Kodiac

Sign in Sign up Account

Author: kodiac

Idebenone

Plain-language summaryIntrigue 65 / 100

Idebenone is a synthetic CoQ10 analog with better blood-brain barrier penetration. Approved in Europe (Raxone) for Leber hereditary optic neuropathy, a rare mitochondrial eye disease. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

47/100

EU-approved Complex I bypass agent with a validated niche in LHON but failed broader neurodegeneration ambitions

Look, idebenone has something most compounds in this library will never have: a European Medicines Agency approval. Raxone is the recognized pharmacological option for Leber hereditary optic neuropathy, a rare mitochondrial complex I disease that produces acute bilateral vision loss in young adults. That regulatory standing is not performative. The mechanism is tested and clinically anchored in a defined population, and thats worth acknowledging up front before we talk about where it falls short.

The core chemistry was developed by Takeda in the 1980s. The short-chain ubiquinone design, replacing CoQ10’s isoprenoid tail with a hydroxyalkyl chain, substantially improves water solubility and, critically, allows idebenone to function as an electron carrier from cytosolic NADH directly to Complex III, bypassing dysfunctional Complex I entirely. In LHON, where Complex I point mutations block normal electron flow and kill retinal ganglion cells, that bypass is the therapeutic logic. The RHODOS trial established meaningful visual acuity preservation in recently affected eyes, and subsequent long-term observational data has held up reasonably well. Mechanism and clinical outcome are genuinely coherent here.

What we don’t like: the broader bets on idebenone have not paid. The Alzheimer program ran through multiple European consortium trials across the 1990s and 2000s, including a reasonably powered study published in 2003 by Gutzmann and colleagues, and produced results that weren’t compelling enough to generate regulatory interest. The Friedreich ataxia program shows some modest cardiac and neurological endpoint signal but no approval. The DELOS trial in Duchenne muscular dystrophy produced a respiratory rate-of-decline signal that remains inconclusive and hasn’t led anywhere definitive. Each new indication gets a plausible rationale and lands in the modest-to-inconclusive range. Thats a pattern.

Against the modern mitochondrial pharmacology landscape, idebenone also faces more interesting competition. SS-31 targets cardiolipin at the inner mitochondrial membrane via a mechanism idebenone doesn’t touch. MOTS-c drives mitochondrial-nuclear retrograde signaling through AMPK and is genuinely novel as a compound class. MitoQ uses triphenylphosphonium conjugation to concentrate at the inner membrane, a more targeted delivery strategy than the water-soluble ubiquinone scaffold. Idebenone’s design was clever for its era; it’s harder to call it differentiated now.

As a bench tool the compound is legitimately useful. Extensive PK data exists, the dose-response literature in cell lines and animal models is well-characterized, and it’s a clean experimental handle for studying Complex I bypass pharmacology in disease-relevant contexts. If your research program involves mitochondrial electron transport dysfunction, idebenone gives you something real to work with. We’d score it higher if the broader program had materialized or if the mechanism were more contemporary. It didnt, and it isn’t, so here we are at 47.

Novelty

25

Mechanism promise

48

In-category differentiation

50

Evidence quality

60

Translational signal

55

Research bench value

52

Rationale Idebenone earns real credibility from EMA approval for LHON and a mechanistically sound electron-shuttle story, but its 1980s origins, Alzheimer program failures, and the emergence of more mechanistically novel mitochondrial compounds keep novelty and differentiation scores firmly mid-range.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Synthetic ubiquinone analog

A short-chain synthetic ubiquinone analog approved in Europe for Leber hereditary optic neuropathy, with reduced lipophilicity and better water solubility than CoQ10.

Abstract

Idebenone (Raxone, Catena, Sovrima; CAS 58186-27-9; molecular formula C19H30O5; molecular weight 338.44) is a synthetic short-chain ubiquinone analog with the 10-carbon isoprenoid tail of CoQ10 replaced by a 10-carbon hydroxyalkyl chain. The structural modification substantially increases water solubility while preserving the redox-cycling quinone chemistry. The compound is approved in Europe (Raxone) for Leber hereditary optic neuropathy, a mitochondrial complex I disease producing acute optic neuropathy. Idebenone bypasses dysfunctional Complex I by directly transferring electrons from cytosolic NADH to Complex III. The compound has also been studied in Alzheimer disease (mixed results, did not advance to FDA approval), Friedreich ataxia (modest effects, no approval), and Duchenne muscular dystrophy. Doses are 900 mg per day in three divided doses for LHON.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-121Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Exenatide

Plain-language summaryIntrigue 75 / 100

Exenatide, sold as Byetta and Bydureon, is the original GLP-1 receptor agonist. It is derived from a peptide in Gila monster saliva (exendin-4). The Bydureon formulation is the long-acting once-weekly version. FDA-approved for type 2 diabetes. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

40/100

First-in-class GLP-1 agonist that defined its category but is now clearly outclassed by semaglutide, tirzepatide, and retatrutide

Look, exenatide has a genuinely interesting origin story. A peptide pulled from Gila monster venom that turned out to be a DPP-4-resistant GLP-1 receptor agonist was a meaningful discovery in 2005 when Byetta first hit the market. Exendin-4’s 53% sequence homology with human GLP-1 but its resistance to enzymatic cleavage was a real structural insight, and the Bydureon once-weekly formulation was a legitimate advance in peptide delivery. The compound helped prove that GLP-1 agonism was a viable therapeutic class. Credit where it’s due.

The problem is that two decades of drug development have clearly moved past it. Semaglutide does everything exenatide does but better: superior HbA1c reduction, more weight loss, strong SUSTAIN and SELECT cardiovascular outcomes data, and now an oral formulation. Tirzepatide adds dual GIP/GLP-1 agonism and produces weight loss figures exenatide couldn’t approach. Retatrutide goes further still with triple agonism. On differentiation, exenatide isn’t just one of many similar agents in its class. It’s actively outclassed by its successors. There’s no serious metric where you’d reach for exenatide over semaglutide when designing new research into GLP-1 biology in metabolic disease.

The one area where exenatide retains genuine research interest is neurodegeneration. The EXENATIDE-PD trial (Athauda et al., 2017, Lancet) reported that subcutaneous exenatide produced improvements in motor scores in Parkinson’s disease that persisted after washout, suggesting disease-modifying rather than purely symptomatic effects. A follow-up trial produced a messier result, which is a familiar pattern in small-N Parkinson’s trials. There’s ongoing work examining GLP-1 receptor signaling in dopaminergic neurons, neuroinflammation, and alpha-synuclein pathology, and exenatide is the probe that carries the most clinical data in that niche. Thats real bench utility, even if it’s narrow.

We’d say the EXENATIDE-PD signal is the one thing that keeps exenatide from being a pure historical artifact. But even there, liraglutide is competing for the same mechanistic questions, and if you’re starting a new CNS-focused GLP-1 program today, you’d probably want to characterize what more potent, newer agonists do in the brain before anchoring to exenatide. The evidence quality for the metabolic indication is genuinely solid, an approved drug with multiple RCTs and real pharmacovigilance data, but strong evidence on an old compound that’s been outperformed doesnt make it a compelling research target. A serious investigator today would only reach for exenatide if extending the EXENATIDE-PD line of work specifically, or needing a well-characterized reference GLP-1 agonist in a head-to-head comparison. Narrow use case. Score reflects it.

Novelty

25

Mechanism promise

38

In-category differentiation

22

Evidence quality

65

Translational signal

60

Research bench value

40

Rationale Exenatide scores low on novelty and differentiation because it has been definitively superseded by newer GLP-1 and dual/triple agonists on every primary metric; its only meaningful residual research angle is the EXENATIDE-PD Parkinson’s neuroprotection signal, which provides modest bench utility but does not rescue the overall score.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

GLP-1 receptor agonist (exendin-4)

A synthetic version of the Gila monster venom peptide exendin-4, FDA-approved as Byetta (twice daily) and Bydureon (weekly) for T2DM.

Abstract

Exenatide (Byetta, Bydureon; CAS 141758-74-9; molecular weight 4186.57) is a synthetic version of exendin-4, a 39-amino-acid peptide originally isolated from Gila monster (Heloderma suspectum) venom. The compound is a GLP-1 receptor agonist with substantial structural difference from human GLP-1, providing resistance to DPP-4 cleavage. Exenatide was the first GLP-1 receptor agonist approved (Byetta, 2005); the extended-release formulation (Bydureon, 2012) provides once-weekly administration. Approved doses are 5 to 10 micrograms twice daily (Byetta) or 2 mg weekly (Bydureon).

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-193Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Lixisenatide

Plain-language summaryIntrigue 60 / 100

Lixisenatide, sold as Adlyxin, is a daily GLP-1 receptor agonist with shorter duration than semaglutide. It particularly affects post-meal blood sugar. Approved for type 2 diabetes. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

38/100

FDA-approved daily GLP-1 agonist largely eclipsed by weekly agents and dual incretins in every meaningful dimension

Look, lixisenatide is a real drug. FDA-approved, well-characterized, multiple phase 3 GetGoal trials with clean methodology. We’re not dismissing it because it’s obscure or poorly understood. We’re scoring it low because it’s been comprehensively lapped by its own pharmacological class.

The structural story is straightforward: Sanofi took exenatide’s backbone, added a six-lysine C-terminal extension, and got a compound with roughly similar GLP-1 receptor affinity but a 3-hour plasma half-life that necessitates once-daily injection. In 2012 that was defensible. By the time it hit US approval in 2016, liraglutide’s once-daily profile was already well-established and semaglutide’s once-weekly trials were underway. The timing was already awkward.

What we find genuinely interesting about lixisenatide, if we’re being honest, is its pharmacodynamic fingerprint. That short half-life produces a predominantly prandial effect: strong postprandial glucose suppression via gastric emptying delay, with relatively modest impact on fasting glucose compared to longer-acting agents. This has been cited as potentially useful in certain T2DM subpopulations where postprandial excursions are the dominant problem and the fasting glucose is already controlled. GetGoal-Duo 1 explored exactly this combination rationale with basal insulin. Thats an interesting pharmacological niche, but its a narrow one.

The differentiation problem is severe. On HbA1c reduction, lixisenatide is roughly comparable to older GLP-1 agents. On body weight, it’s clearly behind semaglutide’s 10-15% in the STEP program and nowhere near tirzepatide’s SURMOUNT numbers. The ELIXA cardiovascular outcomes trial showed non-inferiority, not superiority, for MACE, which puts it well behind semaglutide’s SUSTAIN-6 and LEADER (liraglutide) results. Non-inferiority is a regulatory floor, not a research signal worth chasing.

As a bench tool, there are cleaner GLP-1 probes available. If you’re running GLP-1 receptor biology, exendin-4 is better characterized, semaglutide has a richer literature for chronic studies, and the dual/triple incretins open more interesting mechanistic questions entirely. Lixisenatide sits in an awkward middle ground: too well-known and too outclassed to be a novel research target, but not indispensable enough to be a must-have probe.

We think the research value here is mostly historical and translational-pharmacology at this point. The prandial GLP-1 profile gives it a small niche in basal-bolus combination work. Outside that context, a serious investigator working on GLP-1 receptor biology or metabolic pharmacology in 2025 would pick something else.

Novelty

22

Mechanism promise

42

In-category differentiation

20

Evidence quality

65

Translational signal

58

Research bench value

28

Rationale Lixisenatide scores low on novelty and differentiation because it’s a 2016-approved exenatide derivative with no dual-target angle and clearly inferior weight-loss outcomes versus semaglutide; evidence quality is real (GetGoal phase 3 program, FDA approval) but the translational signal is modest, and bench utility is limited since better GLP-1 probes exist.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

GLP-1 receptor agonist

A daily-dosing GLP-1 receptor agonist FDA-approved 2016 (Adlyxin) for T2DM, structurally derived from exenatide.

Abstract

Lixisenatide (Adlyxin, Lyxumia; CAS 320367-13-3; molecular weight 4858.49) is a 44-amino-acid peptide GLP-1 receptor agonist developed by Sanofi and approved by the FDA in 2016 for T2DM. The compound is structurally derived from exenatide with a six-lysine C-terminal extension. Pharmacokinetics: plasma half-life ~3 hours; once-daily dosing. Approved doses are 10 to 20 mcg subcutaneously daily.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-194Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Lithium Carbonate (Low-Dose)

Plain-language summaryIntrigue 75 / 100

Lithium carbonate is the foundational mood stabilizer for bipolar disorder, in clinical use since the 1950s. At low doses (sometimes called microdose lithium, 1-5 mg) it is sometimes used for cognitive support; at standard psychiatric doses (600-1200 mg) it requires blood level monitoring. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished, active research

45/100

Mechanistically interesting GSK-3β probe held back by decades of inconclusive cognitive trial data

Look, lithium is one of the most mechanistically interesting old compounds in psychiatry, and the low-dose cognitive angle is worth understanding even if the overall picture is disappointing. The core mechanism story is solid: lithium inhibits GSK-3β at the magnesium-binding site, meaning it’s non-ATP-competitive and touches tau phosphorylation, Wnt signaling, and neurogenesis in ways that still matter for modern neurodegeneration research. The inositol monophosphatase axis adds a second real target. Two plausible links to Alzheimer’s pathology, both mechanistically grounded. That part we like.

The clinical record is where it falls apart. The LATTICE trial and most of the small MCI studies have come back with effect sizes barely distinguishable from noise. The epidemiological story is actually more interesting: populations with higher trace lithium in drinking water show lower dementia rates in multiple regional analyses from Europe, Japan, and Texas, but those associations are notoriously confounded and nobody has cleanly bridged from ecological correlation to individual-level causation in a powered RCT. The ALS signal, once moderately promising in preclinical models, largely failed to translate across the 2008-2013 trial wave. Thats a real problem for anyone trying to build a research program around the therapeutic case here.

Novelty is the compound’s biggest liability from a research-merit standpoint. Lithium has been in continuous clinical use since the late 1940s, GSK-3β inhibition has been known since the 1990s, and the low-dose cognitive angle has now generated enough inconclusive data that it’s neither fresh territory nor a solved question. It sits in an awkward middle: too old to be exciting, not resolved enough to be instructive. The literature is large but not convergent, and that’s genuinely frustrating.

What we do think is underappreciated is lithium’s bench value as a reference GSK-3β inhibitor. It’s still widely used in cell culture and organoid work precisely because it’s membrane-permeable, hits the target at low concentrations, and has known pharmacokinetics in virtually every model system. More selective inhibitors like CHIR99021 and SB216763 are now the standard where clean single-target readouts matter, but lithium remains useful when you want broad pathway context or need to compare against historical datasets. Its 75-year pharmacology dossier is actually a bench asset.

Honestly, the sourcing reality is fine and the safety profile at sub-therapeutic doses is better characterized than almost any research compound you’ll handle. But neither of those facts makes low-dose lithium more compelling as a primary research target in 2026. The renal and thyroid monitoring requirements add friction without adding signal, and we’re not optimistic that the next cognitive-indication trial cycle produces the clean positive that has eluded the field for two decades. Worth knowing well. Not worth centering a program on.

Novelty

35

Mechanism promise

55

In-category differentiation

42

Evidence quality

48

Translational signal

38

Research bench value

58

Rationale Lithium’s dual GSK-3β and inositol mechanisms are genuinely multi-target and relevant to tau biology, but the low-dose cognitive indication has failed to produce consistent clinical signal across multiple small RCTs, and novelty is severely constrained by 75 years of continuous clinical use. Bench value as a reference GSK-3β inhibitor keeps the score from collapsing further.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Mood stabilizer (low-dose)

Prescription lithium carbonate at low doses (150-300 mg) studied for cognitive impairment and dementia prevention.

Abstract

Lithium carbonate (CAS 554-13-2) is the principal lithium salt used clinically since 1949 for bipolar disorder, with approved doses providing 600 to 1800 mg lithium ion per day for mood stabilization. Low-dose lithium (providing 150 to 300 mg lithium ion per day, well below therapeutic mood stabilization range) has been studied for cognitive impairment, Alzheimer disease, and ALS with mixed results; effect sizes are small but mechanistically interesting given lithium’s GSK-3 inhibition and inositol monophosphatase effects. Investigators using low-dose lithium should be aware of the still-narrow therapeutic index and potential renal and thyroid effects with chronic use.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-195Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Hordenine

Plain-language summaryIntrigue 35 / 100

Hordenine (N,N-dimethyl-tyramine) is a phenethylamine alkaloid found in germinating barley and several cacti. It is a weak MAO-B inhibitor and a weak monoamine reuptake inhibitor, and the combination slows the breakdown of dopamine and short-lived trace amines like beta-phenylethylamine (PEA). The supplement use angle is to pair it with PEA, where the MAO-B inhibition extends PEA’s normally minutes-long duration into something noticeable. Plasma half-life is one to two hours. The actual pharmacological effects in humans at supplement doses are modest, and most enthusiasm comes from extrapolation rather than human trials. Botanical MAO-B reference compound. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

22/100

Weak botanical MAO-B inhibitor with a narrow PEA-extension niche and no compelling independent research case

Look, hordenine isn’t a bad compound. It’s just not an interesting one, and those are different problems. N,N-dimethyl-tyramine has been in the literature long enough that its pharmacological ceiling is well-understood, and that ceiling is low. Weak MAO-B inhibition, weak monoamine reuptake inhibition, plasma half-life around 1-2 hours. Nothing there surprises anyone who’s read the trace amine literature from the last two decades.

The mechanism isn’t without logic. MAO-B catabolizes beta-phenylethylamine aggressively, which is why PEA’s endogenous half-life is measured in minutes despite its potent monoaminergic effects. Hordenine slows that degradation, so stacking it with PEA extends PEA’s window of action. That’s the entire scientific case for hordenine as a research-relevant compound, and its essentially a delivery-extension story, not a primary mechanism story. We like that the trace amine/TAAR1 space has gotten serious attention in the last decade, but hordenine isnt the probe you reach for when you want to study it properly.

On differentiation, hordenine loses badly to actual pharmacological MAO-B inhibitors. Selegiline is selective, potent, and has a massive preclinical and clinical literature. Rasagiline similarly. Safinamide adds a sodium channel component that gives it real mechanistic depth. Hordenine against those tools is like using a butter knife for something that needs a scalpel. Its botanical origin is sometimes cited as a feature, and we suppose it is if you’re running naturalistic formulation studies, but that’s a thin reason to prioritize it on a serious bench program.

Evidence quality is limited. Theres reasonable in vitro and rodent preclinical data supporting the MAO-B inhibitory activity, but multi-lab replication is sparse and human-facing data at supplement-relevant doses is essentially observational and anecdotal. The pharmacodynamic effects in humans are described uniformly as modest, which is consistent with the weak binding affinities measured in vitro. No robust phase 1 or 2 clinical work anchors the human translation.

Honestly, the only scenario where hordenine earns a place in an active research program is if the program specifically needs a botanical source of mild MAO-B modulation, or if PEA pharmacokinetics are the direct object of study. Both are narrow. Outside those cases, its a mature, well-understood adjunct compound that doesn’t open new questions, doesnt offer unique probe value, and doesn’t differentiate from better tools. A serious investigator would deprioritize this in favor of almost anything else in the phenethylamine or trace amine space.

Novelty

22

Mechanism promise

22

In-category differentiation

18

Evidence quality

25

Translational signal

20

Research bench value

28

Rationale Hordenine scores low across every axis because it’s a decades-old, well-characterized botanical alkaloid whose pharmacology is unremarkable: weak MAO-B inhibition, weak monoamine reuptake inhibition, modest human effect size at supplement doses, and zero differentiation from superior pharmacological tools in its class. Its only credible research angle is as a botanical adjunct extending PEA’s short half-life, which is a narrow probe application rather than a standalone research program.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Phenethylamine MAO-B inhibitor / mild stimulant

N,N-dimethyl-tyramine; a phenethylamine alkaloid found in barley sprouts; a weak MAO-B inhibitor used as a stimulant adjunct.

Abstract

Hordenine (N,N-dimethyl-tyramine; CAS 539-15-1; molecular formula C10H15NO; molecular weight 165.23) is a phenethylamine alkaloid found in germinating barley (Hordeum vulgare) and several cacti. The compound is a weak monoamine oxidase B inhibitor and a weak monoamine reuptake inhibitor; the combined activity slows the degradation of dopamine and trace amines including beta-phenylethylamine (PEA), prolonging their action. Used as a supplement, particularly in combination with PEA where the MAO-B inhibition extends PEA’s normally minutes-long duration. Plasma half-life is approximately 1 to 2 hours. The pharmacological effects in humans at supplement doses are modest. Used as a botanical MAO-B inhibitor in research and in supplement formulations.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-385Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Testosterone (Research)

Plain-language summaryIntrigue 75 / 100

Testosterone is the principal androgen in humans, made from cholesterol in the testes (men) and ovaries plus adrenals (women). It is the foundational compound of androgen pharmacology and the active ingredient in essentially all testosterone replacement therapy plus the backbone of most non-medical anabolic steroid stacks. It binds the androgen receptor directly and is also converted on the fly into dihydrotestosterone (more potent androgen) by 5-alpha-reductase, and into estradiol by aromatase. Sold as cypionate, enanthate, propionate, undecanoate, plus gels and patches, with each ester releasing testosterone over different timescales. Schedule III in the US. The reference androgen receptor agonist for nearly all related research. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundResearch workhorse

44/100

Canonical AR reference compound; foundational but thoroughly mapped, with frontier interest squarely elsewhere

Look, testosterone occupies a genuinely strange position in any research library. It’s the foundational androgen – first isolated by David, Dingemanse, Freud, and Laqueur in 1935, structure confirmed by Butenandt and Ruzicka (Nobel, 1939), and under continuous clinical deployment ever since. At this point, the AR pharmacology is about as well-characterized as receptor biology gets. Ki of roughly 0.5 nM at AR, 5-alpha-reductase conversion to the more potent DHT, aromatase conversion to estradiol. We know this chemistry cold. Thats not a criticism; its just the reality of a compound that has been under rigorous investigation for ninety years across thousands of labs.

The mechanism doesn’t earn novelty points here. Single-receptor agonism in the most saturated steroid class in pharmacology. The interesting research questions around androgen biology, tissue selectivity, AR coactivator recruitment, non-genomic signaling pathways: those are now answered more cleanly with SARMs and selective AR modulators designed specifically to probe those dimensions. If you want to study differential anabolic-to-androgenic ratios, LGD-4033 or RAD-140 are sharper instruments. If you want AR pathway studies without aromatization confound, you need to block aromatase anyway. Testosterone does AR agonism and aromatization simultaneously, which is a physiological feature but a research design confounder.

What actually scores well here is evidence quality and translational signal, and those scores are real. FDA approval for hypogonadism across multiple ester formulations (cypionate, enanthate, propionate, undecanoate). Decades of replicated RCTs, well-characterized PK across routes of administration, solid safety profiling across hematocrit, lipid, and hormonal endpoints. If you’re building a disease model around male hypogonadism or studying androgen-mediated muscle protein synthesis in a clinical context, this is your reference compound, full stop.

Where we find genuine bench value is specifically in the reference probe role. AR binding competition assays, androgen-responsive cell line studies (LNCaP, LAPC4), steroidogenesis pathway models, castration-and-replacement designs in rodents: testosterone is the canonical standard against which everything else is calibrated. That role keeps the bench value score from collapsing. But it’s not a compound you reach for because you’re curious about what it does. You reach for it because you need to establish what something else does relative to it.

Honestly, the overall score here reflects one simple fact: testosterone is so thoroughly understood that the primary research questions it can answer are mostly already answered. The frontier in androgen biology has moved to selective modulators, non-steroidal AR ligands, the androgen receptor splice variants driving castration-resistant prostate cancer, and the complex crosstalk between androgen signaling and metabolic pathways. Testosterone stays in the library as a reference standard and clinical backbone. As an object of primary investigation in 2026, its not where serious investigators are finding new ground.

Novelty

10

Mechanism promise

20

In-category differentiation

42

Evidence quality

80

Translational signal

74

Research bench value

68

Rationale Testosterone scores high on evidence quality and translational signal (FDA-approved, multi-decade RCT base) but bottoms out on novelty and mechanism promise; it’s the prototype AR agonist in the most saturated steroid pharmacology class in existence, and the live research questions in androgen biology are now prosecuted more precisely with SARMs and selective probes. The Schedule III cap (75) does not bind because the weighted score lands well below it.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Endogenous androgen / anabolic-androgenic steroid

The principal endogenous androgen; the foundational compound of androgen pharmacology and the active component of TRT and many AAS regimens.

Abstract

Testosterone (17-beta-hydroxyandrost-4-en-3-one; CAS 58-22-0; molecular formula C19H28O2; molecular weight 288.42) is the principal endogenous androgen, biosynthesized from cholesterol via pregnenolone and progesterone in Leydig cells of the testis (males) and theca cells, ovary, and adrenal cortex (females). The compound is the prototype androgen receptor agonist and the foundation of androgen pharmacology. Pharmacologically, testosterone binds AR (Ki approximately 0.5 nM) and is converted to dihydrotestosterone (DHT) by 5-alpha-reductase (more potent AR agonist) and to estradiol by aromatase (estrogen receptor agonist). Approved as testosterone replacement therapy in male hypogonadism via various ester formulations: cypionate (weekly), enanthate (weekly), propionate (every 2 to 3 days), undecanoate (oral and depot), gels and patches (daily). Schedule III in the US under the CSA. The compound is the foundation of most anabolic-androgenic steroid (AAS) regimens used non-medically for muscle building. Plasma half-life of native testosterone is short (1 to 2 hours); ester formulations release the parent compound over days. Used as the canonical AR agonist in research.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-386Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Estradiol (Research)

Plain-language summaryIntrigue 70 / 100

Estradiol (E2) is the principal endogenous estrogen, made from testosterone and androstenedione by the enzyme aromatase in ovary, fat, brain, and bone tissue. It is a high-affinity full agonist at both estrogen receptor subtypes (ER-alpha and ER-beta), driving classic gene-transcription effects plus rapid membrane-level signaling. Approved across many forms (oral, transdermal patch, gel, vaginal, injectable) for menopausal hormone therapy, postmenopausal osteoporosis prevention, hypoestrogenism in conditions like Turner syndrome, and as part of gender-affirming feminizing therapy. Pharmacokinetics depend heavily on route: oral undergoes large first-pass metabolism, while transdermal forms bypass the liver and produce more physiological plasma levels. Reference estrogen receptor agonist for endocrine research. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundResearch workhorse

45/100

The canonical endogenous estrogen: indispensable as a reference probe, biologically too mapped to excite frontier researchers

Look, estradiol isn’t a research compound in the sense the Kodiac library is trying to surface. It’s the endogenous estrogen. It’s been known since Doisy and Butenandt in the 1920s and 30s, it defines estrogen receptor pharmacology the way glucose defines glycolysis, and the mechanism is so thoroughly described that a first-year grad student can recite it: high-affinity full agonism at both ER-alpha and ER-beta (Ki around 0.1 nM at each), genomic effects through estrogen response elements, rapid non-genomic signaling through membrane-associated ER pools, aromatase as the biosynthetic gateway. There is nothing left to discover about what estradiol IS. The question is only ever what it DOES in some specific tissue, population, or formulation context that hasnt been nailed down yet.

That context matters, because the literature is genuinely enormous. The Women’s Health Initiative, the KEEPS trial, the E3N cohort, decades of transdermal vs oral comparative pharmacokinetics, the whole bioidentical vs conjugated equine estrogens debate, the ER-alpha vs ER-beta tissue selectivity question as it applies to bone, breast, cardiovascular, and CNS targets. The evidence base is as strong as anything in endocrine pharmacology. Multiple approved formulations across oral, transdermal, vaginal, and parenteral routes. If evidence quality alone drove the score, estradiol would be at the top of this list. But evidence quality is 15% of the rubric for a reason.

What we like: estradiol remains the reference probe you can’t avoid. Any investigator running ER biology needs it as a positive control and comparator. It’s the benchmark against which every SERM, SERD, and ER-selective agonist is calibrated. In that narrow but important role, its bench value is genuine and non-negotiable. The ongoing translational signal is also real, particularly in the neuroprotection, cardiovascular, and metabolic contexts where estrogen deprivation models are active research territory.

What we don’t like: as a frontier target, theres almost nothing here. The interesting estrogen receptor biology right now is happening in selective tools. ER-alpha vs ER-beta subtype selectivity probes, tissue-selective ER modulators, SERDs in oncology, the brain-specific ER-X question. Estradiol itself activates everything, which makes it blunt as a discriminating probe. If youre building a new research program around estrogen biology, estradiol is your positive control, not your compound of interest. The novelty score reflects that honestly: this is among the most mature, most-mapped pharmacology in the field.

The score of 45 is the right landing zone. High enough to acknowledge that it’s genuinely important and evidence-rich, low enough to be honest that a serious bench scientist wouldn’t pitch this as an exciting new direction. It’s what you reach for when validating an assay, not when designing a study.

Novelty

10

Mechanism promise

18

In-category differentiation

42

Evidence quality

82

Translational signal

78

Research bench value

72

Rationale Estradiol tanks on novelty and mechanism because ER-alpha/ER-beta pharmacology is among the most exhaustively characterized biology in all of endocrinology; it recovers meaningfully on evidence quality and translational signal (decades of RCTs, multiple approvals) and holds respectable bench value as the canonical ER reference probe, but that utility is increasingly eclipsed by selective ER modulators and degraders that can discriminate receptor subtype biology more cleanly.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Endogenous estrogen / ER-alpha and ER-beta agonist

17-beta-estradiol; the principal endogenous estrogen and the foundational compound of estrogen pharmacology.

Abstract

Estradiol (17-beta-estradiol, E2; CAS 50-28-2; molecular formula C18H24O2; molecular weight 272.39) is the principal endogenous estrogen, biosynthesized from testosterone (and androstenedione) by aromatase in ovary, adipose tissue, brain, and bone. The compound is a high-affinity full agonist at estrogen receptors ER-alpha and ER-beta (Ki approximately 0.1 nM at both), with downstream genomic effects on estrogen-responsive gene transcription and rapid non-genomic effects through membrane-associated signaling. Approved indications include menopausal hormone therapy (multiple oral, transdermal, vaginal, and parenteral formulations), prevention of postmenopausal osteoporosis, hypoestrogenism (Turner syndrome), and as part of gender-affirming feminizing hormone therapy. Pharmacokinetics depend strongly on formulation: oral micronized estradiol undergoes substantial first-pass metabolism; transdermal forms (patches, gels, sprays) bypass first-pass and produce more physiological plasma levels. Schedule N (non-controlled). Used as the canonical estrogen receptor agonist in research.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-387Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Progesterone (Research)

Plain-language summaryIntrigue 65 / 100

Progesterone is the principal endogenous progestogen, built from cholesterol via pregnenolone in the corpus luteum, adrenal cortex, and (in pregnancy) placenta. It activates the progesterone receptor with high affinity and also has interesting side effects: it antagonizes mineralocorticoid receptors (driving sodium loss) and its metabolite allopregnanolone is a powerful positive modulator of GABA-A receptors (driving sedation). Approved for menopausal hormone therapy paired with estrogen for endometrial protection, IVF luteal support, secondary amenorrhea, and preterm birth prevention. Oral micronized progesterone hits the liver hard and produces sedating allopregnanolone, while vaginal and transdermal forms give cleaner PR effects. Plasma half-life of the parent is short (5 to 20 minutes). Canonical PR agonist. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

48/100

Canonical endogenous PR agonist; mature approved-drug evidence base, low novelty, infrastructure-grade bench tool

Look, progesterone is the compound you already have on the bench before you start designing experiments. It’s the canonical endogenous progestogen, the reference PR agonist against which everything else in its class gets compared. That’s a real and meaningful role. It’s just not what makes something an exciting research target in 2026.

The mechanism is worth unpacking because its actually more layered than the single-receptor framing suggests. High-affinity PR agonism drives the reproductive and endometrial effects everyone knows. Weak glucocorticoid receptor activity produces a mineralocorticoid-antagonist fingerprint that contributes to natriuretic effects. And first-pass hepatic conversion to allopregnanolone produces GABA-A positive allosteric modulation — which is why oral micronized progesterone (Prometrium) reliably produces sedation in a way vaginal forms don’t. That last piece is where the most interesting current biology lives. Brexanolone, which is essentially IV allopregnanolone, got FDA approval for postpartum depression in 2019, and the neurosteroid GABA-A PAM space is genuinely active right now. But the excitement is about synthetic neurosteroid analogs — zuranolone, ganaxolone, next-generation GABA-A selective compounds. Progesterone the compound is upstream infrastructure for that story, not the lead character.

The evidence base is as mature as it gets for a non-blockbuster pharmaceutical. Multiple phase 3 RCTs, approved across HRT, assisted reproductive technology, secondary amenorrhea, and intramuscular preterm birth prevention. The translational arrow is solid for those established uses. Where it gets instructive: the TBI neuroprotection story once looked promising. ProTECT II phase 2 showed signal, the mechanistic rationale was plausible, and then the ProTECT III trial was definitively negative. That failure matters — it’s a clean example of how compelling preclinical work and early phase 2 signal can collapse under a well-powered phase 3, and it appropriately cooled enthusiasm for progesterone as a neuroprotective research target.

For bench use, progesterone is straightforward infrastructure. It’s the reference standard for PR biology, reproductive physiology studies, and neurosteroid pathway work. Sourcing is genuinely easy — multiple suppliers with USP/EP-grade material, well-characterized reference standards widely available. Reconstitution for in vitro work is routine in ethanol or DMSO. Nothing technically demanding here.

What we dont love: novelty is essentially nil for the compound itself in 2026. The frontier science is at the level of synthetic neurosteroid analogs and selective PR modulators, not progesterone as a primary investigational compound. If you’re building a research program, progesterone is part of your toolkit, not your lead. It earns its place as a reference standard and a component of neurosteroid pathway studies, but it’s not where you’d place your exploratory bets. Score accordingly.

Novelty

20

Mechanism promise

40

In-category differentiation

45

Evidence quality

72

Translational signal

68

Research bench value

60

Rationale Progesterone is the reference-standard PR agonist with a thoroughly characterized multi-receptor pharmacology (PR, weak GR, GABA-A via allopregnanolone metabolite) and an approved-drug evidence base spanning HRT, ART, and preterm birth prevention. The interesting neurosteroid science has largely migrated to synthetic analogs like zuranolone and ganaxolone; progesterone itself scores low on novelty and differentiation, pulling the overall to 48 despite solid evidence and translational signal.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Endogenous progestogen / PR agonist

The principal endogenous progestogen; a progesterone receptor agonist with luteal phase, gestational, and neurosteroid functions.

Abstract

Progesterone (pregn-4-ene-3,20-dione; CAS 57-83-0; molecular formula C21H30O2; molecular weight 314.46) is the principal endogenous progestogen, biosynthesized from cholesterol via pregnenolone in the corpus luteum, adrenal cortex, and (during pregnancy) placenta. The compound is a high-affinity progesterone receptor (PR) agonist with secondary effects at the glucocorticoid receptor (mineralocorticoid antagonism contributing to natriuretic effects) and at GABA-A receptors (the pregnanolone metabolite is a positive allosteric modulator producing sedation). Approved indications: menopausal hormone therapy (combined with estrogen for endometrial protection in women with intact uterus), assisted reproductive technology luteal support, secondary amenorrhea, and prevention of preterm birth (intramuscular formulation). Oral micronized progesterone (Prometrium) is highly subject to first-pass metabolism producing the sedating allopregnanolone metabolite; vaginal and transdermal forms produce more direct PR effects with less sedation. Plasma half-life is short (5 to 20 minutes for parent; metabolites variable). Used as the canonical PR agonist in research.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-388Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Oxandrolone

Plain-language summaryIntrigue 55 / 100

Oxandrolone (Anavar, Oxandrin) is a synthetic anabolic steroid developed by Searle in 1962. The 17-alpha-alkylation makes it orally active by blocking liver breakdown, and the 2-oxa substitution shifts the profile toward anabolic (muscle-building) over androgenic (masculinizing) effects in standard assays. FDA-approved for severe weight loss after surgery, trauma, infection, or chronic illness, plus bone pain in osteoporosis. Burn recovery is the cleanest clinical use case, where AAS protocols have solid evidence. HIV wasting is another approved indication. In the gym world it is one of the most commonly diverted oral AAS because users perceive a relatively favorable side-effect profile. Schedule III. Hepatotoxic at high doses owing to the alkylation. Reference 17-alpha-alkylated oral AAS. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

39/100

Mature clinical AAS with replicated burn-recovery evidence but no novel mechanism or frontier research angle

Look, oxandrolone isnt a mystery. Searle synthesized it in 1962, the FDA approved it as Oxandrin, and its mechanism has been understood for decades. As a research compound it occupies a specific and well-defined niche: the canonical reference 17-alpha-alkylated oral AAS. That role gives it some legitimate bench value even now, but it doesnt make it an exciting primary research target.

The mechanism story is completely unsurprising. AR agonism with a higher anabolic-to-androgenic ratio than testosterone, achieved through the 2-oxa substitution at carbon-2 and the 17-alpha methyl group that confers oral activity by resisting hepatic first-pass metabolism. The Hershberger assay work defining its A:A ratio was done a long time ago. What you’re getting is a well-mapped receptor binding profile with no novel target biology, no dual or multi-target mechanism, and no new pharmacology. Single-receptor agonism in a saturated class is about as far from the frontier as you can get.

The clinical evidence is where this compound actually earns points. Burn recovery is one of the more rigorously studied applications of any AAS; pediatric burn trials and adult catabolic wasting data have been replicated across multiple institutions and form the basis of FDA approval. The HIV wasting indication is similarly evidence-backed. This isnt single-lab data or anecdote. There are genuine RCTs, modest N but replicated, and the translational signal in severe catabolic states is real. For a researcher studying anabolic signaling under physiological stress, oxandrolone is a legitimate clinical reference point with a credible evidentiary floor.

That said, nobody picking up oxandrolone for a new program is doing so because it opens a novel mechanistic door. Its differentiation within the AAS class is real but narrow: it’s the oral 17aa benchmark, the compound you reach for when you need a controlled comparison for hepatotoxicity studies or anabolic-to-androgenic ratio methodology. Thats a niche that matters, but it wont pull a lab into new territory. The interesting open questions, long-term IGF-1 modulation, interaction with the GH axis in burn patients, comparative hepatic impact of 17aa structures, are well-known to AAS specialists already and not the kind of questions attracting broad investigator interest in 2025.

What we like: FDA approval, replicated burn data, clean reference profile for comparative 17aa work. What we dont like: the mechanism has no new angles, the literature is decades old, and Schedule III classification adds real procurement and handling overhead for a compound that is unlikely to produce a surprising result. For a general research program not already invested in anabolic pharmacology, theres not much here that earns bench time over newer targets.

Novelty

18

Mechanism promise

22

In-category differentiation

35

Evidence quality

68

Translational signal

63

Research bench value

45

Rationale Oxandrolone scores low on novelty and mechanism because it is a fully mapped AR agonist from 1962 with no dual-target or novel pharmacology; it recovers modestly on evidence and translational signal through replicated RCTs in burn recovery and HIV wasting, and carries narrow bench value as the canonical reference 17-alpha-alkylated oral AAS. The Schedule III cap at 75 does not bind because the raw weighted score lands at 39.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

17-alpha-alkylated oral anabolic steroid

A 17-alpha-alkylated synthetic anabolic steroid; clinically used in burn recovery and HIV wasting; widely used in non-medical AAS contexts.

Abstract

Oxandrolone (17-beta-hydroxy-17-alpha-methyl-2-oxa-5-alpha-androstan-3-one; CAS 53-39-4; molecular formula C19H30O3; molecular weight 306.44) is a 17-alpha-alkylated synthetic anabolic-androgenic steroid (AAS) developed by Searle in 1962 and approved by the FDA (Anavar, Oxandrin) for severe weight loss following surgery, trauma, infection, or chronic illness; for relief of bone pain in osteoporosis; and for compensation of catabolic states. Mechanism: AR agonism (lower than testosterone but with relatively higher anabolic-to-androgenic ratio in the Hershberger assay). The 2-oxa substitution and 17-alpha alkylation produce oral activity (resistance to first-pass hepatic metabolism) and a more anabolic profile relative to androgenic. Plasma half-life is approximately 9 hours. Schedule III in the US under the CSA. Used in burn recovery (where AAS clinical use is well-established) and in HIV wasting; the most commonly diverted oral AAS for non-medical bodybuilding owing to a perceived favorable side effect profile. Used as a reference 17-alpha-alkylated oral AAS in research.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-389Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Stanozolol

Plain-language summaryIntrigue 48 / 100

Stanozolol (Winstrol) is a 17-alpha-alkylated synthetic anabolic steroid developed by Sterling-Winthrop in 1962, distinguished by a pyrazole ring fused to the steroid A-ring. The fusion shifts the anabolic-to-androgenic ratio higher than testosterone and supports oral activity. FDA-approved historically for hereditary angioedema (largely replaced now by C1-inhibitor and icatibant) and a few other niche uses. Its place in popular memory belongs to Ben Johnson, whose 1988 Seoul Olympic 100m gold medal was stripped after a positive stanozolol test. Hepatotoxicity is the main limiting concern, the standard cost of 17-alpha-alkylation. Schedule III. Used in research as a reference oral AAS. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

37/100

A historically significant reference AAS with mature mechanism and declining research relevance

Look, stanozolol is not a mystery. It’s been around since 1962, it made Ben Johnson the most famous disqualified sprinter in history, and the mechanism is what you’d expect: androgen receptor agonism via a pyrazol-fused 17-alpha-alkylated backbone that shifts the anabolic-to-androgenic ratio favorably relative to testosterone. Sterling-Winthrop knew what they were doing structurally. But knowing what something does and finding it interesting in 2026 are different things.

The mechanism story starts and ends with AR binding. The pyrazole fusion at the A-ring is chemically clever for its era, and the oral bioavailability is real. What isn’t real anymore is the clinical urgency. The hereditary angioedema indication that got Winstrol its FDA approval has been largely displaced by C1-inhibitor concentrates and icatibant. Those agents are cleaner, better-tolerated, and don’t carry the hepatotoxicity liability that 17-alpha-alkylated steroids all share to varying degrees. The indication that justified the compound’s existence in the clinic is essentially a historical artifact at this point.

What we’re left with is a Schedule III reference compound. That’s not nothing. If you’re running AAS pharmacology studies, SHBG displacement work, or comparative androgen receptor affinity panels, stanozolol occupies a specific and well-characterized position in the reference set. The literature is extensive enough that you can contextualize your findings against a real body of evidence. That’s the bench value argument, and it’s legitimate but limited. Newer AAS analogs with more interesting selectivity profiles have appeared in the literature if your goal is genuinely advancing the mechanistic frontier.

The evidence quality is actually respectable for what it is. FDA approval, multi-decade use, clear pharmacokinetics, well-characterized toxicity. But high evidence quality on a mature well-understood compound is almost a negative signal for research interest. It means the question has already been answered. There’s no ambiguity left to resolve with stanozolol that hasn’t already been resolved, which is why the novelty score sits at the floor and drags the overall down hard.

Honestly, if you’re building a research program around androgen biology in 2026, the interesting questions are in selective androgen receptor modulators, tissue-selective AAS fragments, or non-steroidal AR modulators. Stanozolol tells you where that field came from, not where it’s going. We think it earns its place in the library as a reference compound, but we’d be doing investigators a disservice if we scored it as if it were an active frontier.

Novelty

18

Mechanism promise

22

In-category differentiation

35

Evidence quality

60

Translational signal

55

Research bench value

48

Rationale Stanozolol scores low on novelty and mechanism because it’s a 1962 oral AAS with well-understood AR agonism and an indication space that modern therapy has largely superseded; evidence quality and translational signal are genuine given FDA approval and decades of clinical use, but those points are offset by near-zero novelty and limited differentiation from a saturated class. Schedule III cap (75) does not bind; the raw weighted score of 37 reflects the compound’s historical-reference-only status.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

17-alpha-alkylated heterocyclic AAS

A pyrazol-fused 17-alpha-alkylated AAS; the steroid involved in the Ben Johnson 1988 Olympic doping case; clinically used historically for hereditary angioedema.

Abstract

Stanozolol (17-beta-hydroxy-17-alpha-methyl-5-alpha-androstano[3,2-c]pyrazole; CAS 10418-03-8; molecular formula C21H32N2O; molecular weight 328.49) is a pyrazol-fused 17-alpha-alkylated synthetic AAS developed by Sterling-Winthrop in 1962 and approved by the FDA (Winstrol) for hereditary angioedema and other indications. The pyrazole fusion at the A-ring increases the anabolic-to-androgenic ratio relative to testosterone and supports oral activity. Plasma half-life is approximately 9 hours (oral). Schedule III. The compound’s place in popular culture is dominated by the Ben Johnson case at the 1988 Seoul Olympics, where his 100m gold medal was stripped after positive testing for stanozolol. The clinical use in hereditary angioedema (rare, often replaced by C1-INH or icatibant in modern practice) demonstrates the compound’s effect on hepatic protein synthesis. Hepatotoxicity is the principal limitation. Used as a reference oral AAS in research.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-390Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026

←Previous Page

1 … 44 45 46 47 48 … 69

Bench-grade research compounds. Cited research. Verified COAs.

kodiac.bio

Explore

Shop
Monographs
Lab Results
About
Affiliate program
Affiliate handbook

Account

Cart
My account

Help

Compliance
Contact

Quarterly dispatch

New batches and new monographs only. Unsubscribe in one click.

Write to us from the contact page to join the list.

Kodiac biolabs sells research compounds for in vitro and in vivo investigative purposes only. Products are not for human or veterinary consumption. Not for medical, diagnostic, or therapeutic use. By using this site you confirm you are acquiring research compounds for research purposes only.

Kodiac biolabs is not affiliated with the U.S. Food and Drug Administration. Products are research reagents, have not been evaluated by the FDA, and are not intended to diagnose, treat, cure, or prevent any disease.

© 2026 Kodiac biolabs LLC. All rights reserved.